Sandoz resubmission puts Amgen's Neulasta at further risk of competition

Sandoz resubmission puts Amgen's Neulasta at further risk of competition

Submitted by admin on April 3, 2019 - 9:31pm
Source: 
Biopharma Dive
News Tags: 
FDA
Novartis
biosimilars
Sandoz
Amgen
Neulasta
Headline: 
Sandoz resubmission puts Amgen's Neulasta at further risk of competition
snippet: 

Nearly three years after the FDA rejected the Novartis unit's biosimilar application, the company is trying again.

Do Not Allow Advertisers to Use My Personal information